Fig. 6

Identification and validation of specific gene signatures that could discriminate hNTSCs with superior efficacy. (A) Heatmap analysis revealed 15 differential expressed genes in hNTSCs by immunomodulatory capacity. Group A: 11 donor-derived hNTSCs with no efficacy against CIA; Group B: 7 donor-derived hNTSCs with significant suppression of CIA. (B) Differential gene expression levels between Group A_hNTSCs and Group B_hNTSCs. Featured genes are marked. (C) Validation of featured gene expression by the Taqman qPCR method. Sixteen donor-derived hNTSCs were tested in duplicate (mean ± SD). *P < 0.05; **P < 0.01.